Cardiovascular side effects and the early use of ADT — another large data set analysis

A newly published paper in BJU International has expanded our understanding of the cardiovascular risks associated with the use of androgen deprivation therapy (ADT) — most particularly in older men treated with ADT as their first-line form of therapy. … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist? Part II

Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …

Can the new hormone therapies actually replace the older ones?

Here is a question that is on the minds of many physicians and patients on Planet Prostate Cancer today: Can treatment with abiraterone acetate or similar agents replace the continuous and/or the intermittent first-line use of LHRH-agonist–induced medical castration in patients with high-risk and advanced forms of prostate cancer? … READ MORE …

Recovery of serum T levels after short-term LHRH agonist therapy

An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist. … READ MORE …

Does switching LHRH agonists have a real clinical benefit?

There are two potentially good reasons for a patient who is receiving treatment with an LHRH agonist to switch from one product to another: the first is because he is having a problem with the adverse effects of his initial LHRH therapy; the second is because he has a rising PSA on the initial LHRH agonist. … READ MORE …

Colorectal cancer among prostate cancer patients treated with ADT

As if it wasn’t long enough already, the list of adverse events “associated with” the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is growing. … READ MORE …

Changes in use of LHRH agonists between 2003 and 2005 and related matters

Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years. … READ MORE …

The LHRH “flare” reaction: do we really know what we thought we knew?

While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem of disease “flare” associated with this first injection of the LHRH. … READ MORE …

Prostate cancer news reports: Thursday, July 9, 2009

Today’s news reports address such items as:

  • Finasteride in the prevention of prostate cancer
  • Nitric oxide treatment in men with a rising PSA after first-line therapy
  • Decreased use of LHRH agonist therapy since 2003 … READ MORE …

Prostate cancer news reports: Tuesday, June 16, 2009

This morning’s news reports address:

  • Patterns of use of PSA and DRE testing in the USA
  • The value of ADT in men receiving combined brachytherapy + EBRT
  • Skeletal and cardiovascular adverse effects of ADT
  • LHRH agonist treatment and effects on LHRH agonist receptors … READ MORE …

Prostate cancer news reports: Tuesday, May 12, 2009

Today’s news reports cover items on:

  • The feasibility of gene expression analysis and prostate cancer prognosis
  • The potential of color Döppler ultrasound to assess prostate cancer risk
  • Radical perineal prostatectomy and quality of life in Japanese patients
  • Outcomes and satisfaction with treatment among patients < 65 years of age
  • LHRH agonist therapy and cognitive dysfunction … READ MORE …

Tuesday’s news update: December 23, 2008

Today’s news items deal with timing of hormone therapy for men with lymph node-positive prostate cancer, the impact of adjuvant LHRH agonist therapy on cardiovascular mortality in men receiving radiotherapy for locally advanced prostate cancer, and the status of the epothilones in treatment of metastatic prostate cancer. … READ MORE …